NEW YORK (
) hit a new 52-week low Wednesday as it is currently trading at $9.35, below its previous 52-week low of $9.41 with 1.5 million shares traded as of 3:55 p.m. ET. Average volume has been two million shares over the past 30 days.
Amylin has a market cap of $1.4 billion and is part of the
industry. Shares are down 32% year to date as of the close of trading on Tuesday.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases.
- Practice your AMLN trading strategies and win cash in our stock game.
TheStreet Ratings rates Amylin as a
. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management. You can view the full
or get investment ideas from our